Darolutamide 300mg tablets
NHS hospitals in England used £236,221,578 of indicative cost of Darolutamide 300mg tablets in the 12 months to July 2026, about 0.9% of all hospital medicines spend. That is up 75.1% on the previous 12 months.
Indicative cost · 12 months
Quantity (VMP units) · 12 months
Share of hospital medicines spend
Figure 1. Darolutamide 300mg tablets: NHS hospital indicative cost by month (£ millions)
Source: NHSBSA Secondary Care Medicines Data, to July 2026
Cost is indicative — actual hospital medicine prices are commercially confidential, so these figures are estimated from list prices. See methodology.
NHS trusts using Darolutamide 300mg tablets most
By indicative cost over the 12 months to July 2026.
| NHS trust | Indicative cost (12 months) |
|---|---|
| East And North Hertfordshire Nhs Trust | £8,644,554 |
| Portsmouth Hospitals Nhs Trust | £8,394,038 |
| Derby Teaching Hospitals Nhs Found Trust | £7,950,936 |
| Royal Surrey County Hosp Nhs Found Trust | £6,979,100 |
| The Christie Nhs Foundation Trust | £6,869,010 |
| The Clatterbridge Cancer Centre Nhs Ft | £6,334,684 |
| Sheffield Teaching Hospitals Nhs Trust | £5,585,516 |
| Royal Cornwall Hospitals Nhs Trust | £5,548,940 |
| The Royal Marsden Nhs Foundation Trust | £5,283,166 |
| Southend Univ Hosp Nhs Foundation Trust | £5,148,980 |
The primary-care picture
No confident match to a community-dispensed medicine was found for this product, so no primary-care comparison is shown. SCMD products are recorded at product level, which does not always map cleanly to a BNF substance.